CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 37 enrolled
Drug / intervention
Neomycin +2 moredrug
Likely dose
Neomycin 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00945334
NCT00945334N/ACompleted
CompareCT.gov

Double-blind, Placebo Controlled Trial Comparing Neomycin to Rifaximin Plus Neomycin in the Treatment of Methane Positive Subjects With Constipation-predominant Irritable Bowel Syndrome

Mark Pimentel, MD·interventional·Posted Jul 24, 2009·Updated Aug 10, 2015

In Brief

A clinical study evaluating Neomycin, Placebo, and 1 other intervention for Constipation-predominant Irritable Bowel Syndrome. Completed, enrolled 37 participants across 2 sites.

Detailed Summary

In this study the investigators aim to compare the efficacy of neomycin to a combination of rifaximin and neomycin in the treatment of C-IBS subjects with methane on their breath test. This study will be conducted in collaboration with Dr. John DiBaise at the Mayo Clinic in Scottsdale, AZ and Dr. Satish Rao in Georgia Regents University in Augusta, GA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsConstipation-predominant Irritable Bowel Syndrome
CountriesUnited States
CollaboratorsBausch Health Americas, Inc.

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 24, 2009
Enrollment StartAug 1, 2009
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 16.9 years ago

Interventions

Neomycindrug

500 mg po bid for 14 days

Placebodrug

placebo for 14 days tid

Rifaximindrug

550 mg po tid